Pharmacodynamic and Pharmacokinetic Study of PL-ASA
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a
novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose